[go: up one dir, main page]

MX2024007929A - Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead. - Google Patents

Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.

Info

Publication number
MX2024007929A
MX2024007929A MX2024007929A MX2024007929A MX2024007929A MX 2024007929 A MX2024007929 A MX 2024007929A MX 2024007929 A MX2024007929 A MX 2024007929A MX 2024007929 A MX2024007929 A MX 2024007929A MX 2024007929 A MX2024007929 A MX 2024007929A
Authority
MX
Mexico
Prior art keywords
yap
taz
tead
tetrahydropyrazolopyrimidines
inhibition
Prior art date
Application number
MX2024007929A
Other languages
English (en)
Inventor
Arnaud Marchand
Wim Smets
Bart Vanderhoydonck
Matthias Versele
Ii Stephen L Gwaltney
Amuri Kilonda
Aurélie Candi
Original Assignee
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath filed Critical Univ Leuven Kath
Publication of MX2024007929A publication Critical patent/MX2024007929A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción se refiere a compuestos novedosos, a dichos compuestos para su uso como un fármaco, más particularmente para la prevención o el tratamiento de enfermedades mediadas por la actividad de la transcripción de YAP/TAZ-TEAD, aún más particularmente para la prevención o el tratamiento del cáncer o la fibrosis. La presente descripción también se refiere a un método para la prevención o el tratamiento de dichas enfermedades que comprende el uso de los compuestos novedosos.
MX2024007929A 2021-12-23 2022-12-23 Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead. MX2024007929A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293538P 2021-12-23 2021-12-23
PCT/US2022/082327 WO2023122783A2 (en) 2021-12-23 2022-12-23 Tetrahydropyrazolopyrimidines and related analogs for inhibiting yap/taz-tead

Publications (1)

Publication Number Publication Date
MX2024007929A true MX2024007929A (es) 2024-09-10

Family

ID=86903815

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007929A MX2024007929A (es) 2021-12-23 2022-12-23 Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.

Country Status (14)

Country Link
US (1) US20230279016A1 (es)
EP (1) EP4452254A4 (es)
JP (1) JP2025501773A (es)
KR (1) KR20240137563A (es)
CN (1) CN118613257A (es)
AR (1) AR128110A1 (es)
AU (1) AU2022419653A1 (es)
CL (1) CL2024001894A1 (es)
CO (1) CO2024009582A2 (es)
IL (1) IL313630A (es)
MX (1) MX2024007929A (es)
PE (1) PE20250833A1 (es)
TW (1) TW202333679A (es)
WO (1) WO2023122783A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025534549A (ja) 2022-09-29 2025-10-16 インシリコ メディシン アイピー リミテッド Ｔｅａｄ阻害剤およびその使用の方法
WO2025019604A2 (en) * 2023-07-18 2025-01-23 The General Hospital Corporation Proteolysis targeting chimeras for treating neurodegeneration
WO2025088534A1 (en) * 2023-10-27 2025-05-01 Dong-A St Co., Ltd. Bicyclic heterocycle compounds as tead inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3539961T3 (pl) * 2015-06-29 2022-02-14 Astrazeneca Ab Policykliczne pochodne amidowe jako inhibitory CDK9
CN112204029B (zh) * 2018-05-31 2024-03-01 豪夫迈·罗氏有限公司 治疗性化合物
AR123656A1 (es) * 2020-09-30 2022-12-28 Univ Leuven Kath Derivados de 1,2,3,4-tetrahidroquinolina

Also Published As

Publication number Publication date
KR20240137563A (ko) 2024-09-20
CL2024001894A1 (es) 2024-12-06
IL313630A (en) 2024-08-01
US20230279016A1 (en) 2023-09-07
CN118613257A (zh) 2024-09-06
EP4452254A4 (en) 2025-12-31
TW202333679A (zh) 2023-09-01
WO2023122783A2 (en) 2023-06-29
WO2023122783A3 (en) 2023-08-24
CO2024009582A2 (es) 2024-10-21
JP2025501773A (ja) 2025-01-23
EP4452254A2 (en) 2024-10-30
AU2022419653A1 (en) 2024-07-18
AR128110A1 (es) 2024-03-27
PE20250833A1 (es) 2025-03-21
WO2023122783A8 (en) 2024-07-25

Similar Documents

Publication Publication Date Title
MX2024007938A (es) Indoles, indazoles y analogos relacionados para inhibir yap/taz-tead.
AR128107A1 (es) Anilinas de 2-pirazol y análogos relacionados para inhibir yap / taz-tead
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
MX2024007929A (es) Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.
CO2021015318A2 (es) Compuestos y métodos para el tratamiento de covid-19
CL2023000921A1 (es) Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead
DOP2018000222A (es) Inhibidores de mcl1 macrocíclicos para tratar el cáncer antecedentes
MX2022007515A (es) Inhibidores de sos1.
ECSP20033467A (es) Compuestos macrocíclicos para tratar enfermedades
MX2022001697A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
CO2018005640A2 (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
AR111495A1 (es) Compuestos de imidazo-piperidina fusionada como inhibidores de jak
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
UY38174A (es) Benzofurano, benzopirrol, benzotiofeno sustituidos y otros compuestos relacionados, como inhibidores del complemento
CL2021001656A1 (es) Compuestos de imidazopiridina e imidazopiridina y sus usos.
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
ECSP22044525A (es) Terapia de combinaci?n que comprende un inhibidor de alk2 y un inhibidor de jak2
MX2024015493A (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1
CL2017001275A1 (es) Análogos ligados de urea sustituidos como moduladores de sirtuina
AR127470A1 (es) Inhibidores de lrrk2
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
MX2024007937A (es) Tetrahidrobenzoazepinonas y analogos relacionados para la inhibicion de yap/taz-tead.
MX2021012544A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.